These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1278 related articles for article (PubMed ID: 8900920)
1. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions. Korabiowska M; Brinck U; Mirecka J; Kellner S; Marx D; Schauer A In Vivo; 1995; 9(5):433-8. PubMed ID: 8900920 [TBL] [Abstract][Full Text] [Related]
2. Differential expression of cerbB3 in naevi and malignant melanomas. Korabiowska M; Mirecka J; Brinck U; Hoefer K; Marx D; Schauer A Anticancer Res; 1996; 16(1):471-4. PubMed ID: 8615656 [TBL] [Abstract][Full Text] [Related]
3. Bcl2 and Bax expression in naevi and melanomas and their relation to ploidy status and proliferation. Korabiowska M; Brinck U; Ruschenburg I; Schlott T; Droese M; Stachura J Pol J Pathol; 1999; 50(1):17-21. PubMed ID: 10412270 [TBL] [Abstract][Full Text] [Related]
4. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497 [TBL] [Abstract][Full Text] [Related]
5. Significance of P-53 antigen in malignant melanomas and naevi of the head and neck area. Korabiowska M; Brinck U; Hoenig JF; Bartkowski SB; Kellner S; Marx D; Schauer A Anticancer Res; 1995; 15(3):885-9. PubMed ID: 7645976 [TBL] [Abstract][Full Text] [Related]
6. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Nasr MR; El-Zammar O Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113 [TBL] [Abstract][Full Text] [Related]
7. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331 [TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of primary cutaneous melanoma and clinical outcome. Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A; J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. Dai DL; Martinka M; Li G J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123 [TBL] [Abstract][Full Text] [Related]
10. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma. Ramsden AJ; Grover R; Chana J; Tulley P; Sanders R; Wilson GD J Plast Reconstr Aesthet Surg; 2007; 60(6):626-30. PubMed ID: 17485049 [TBL] [Abstract][Full Text] [Related]
11. Use of oncogene expression as an independent prognostic marker for primary melanoma. Grover R; Pacifico MD; Wilson GD; Sanders R Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057 [TBL] [Abstract][Full Text] [Related]
12. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of some markers in cutaneous melanoma treated with different therapeutic modalities]. Nepomniashchaia EM; Gusareva MA; Petrov SV Vopr Onkol; 2008; 54(6):744-8. PubMed ID: 19241851 [TBL] [Abstract][Full Text] [Related]
14. Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance. Chen N; Gong J; Chen X; Meng W; Huang Y; Zhao F; Wang L; Zhou Q Hum Pathol; 2009 Jul; 40(7):950-6. PubMed ID: 19269012 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma. Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286 [TBL] [Abstract][Full Text] [Related]
16. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Mouawad R; Spano JP; Comperat E; Capron F; Khayat D Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860 [TBL] [Abstract][Full Text] [Related]
17. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. Kalogeraki A; Garbagnati F; Darivianaki K; Delides GS; Santinami M; Stathopoulos EN; Zoras O Anticancer Res; 2006; 26(5A):3551-4. PubMed ID: 17094481 [TBL] [Abstract][Full Text] [Related]
18. Novel role for RGS1 in melanoma progression. Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492 [TBL] [Abstract][Full Text] [Related]
19. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Kraehn GM; Utikal J; Udart M; Greulich KM; Bezold G; Kaskel P; Leiter U; Peter RU Br J Cancer; 2001 Jan; 84(1):72-9. PubMed ID: 11139316 [TBL] [Abstract][Full Text] [Related]
20. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma. Thies A; Schachner M; Berger J; Moll I; Schulze HJ; Brunner G; Schumacher U J Pathol; 2004 Aug; 203(4):933-9. PubMed ID: 15258996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]